News

AstraZeneca has reported the results of the phase II studies, onset/offset and respond for Ticagrelor (Brilinta) at the annual American Heart Association (AHA) scientific sessions in Orlando, FL.

Genzyme’s Lumizyme failed to receive approval from the FDA for the treatment of pompe disease. The FDA issued a complete response letter (CRL) stating that the agency will

Evotec has been granted up to E2.5m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase

IsoRay has signed a distribution agreement with Inter V Medical of Montreal, Quebec, Canada. Inter V Medical will have rights to sell Cesium-131 brachytherapy seeds in Canada, which

The 1st user meeting on protein arrays in clinical applications was organised by Protagen, Germany. It focused on the increasing relevance of new markers and marker panels for

Pfizer has submitted pediatric data for Lipitor (atorvastatin) to the EMEA. Reportedly, Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5mg dose, which

Formatech has selected Kai Pharmaceuticals (Kai) and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program. Formatech plans to complete

Under these licensing agreements, EraGen will have access to Illumina’s BeadXpress platform for the continued development and commercialisation of molecular-based, high-throughput clinical multiplexed assays with its unique, patented

Takeda Pharmaceutical (Takeda) has reported that TAK-438, an acid-related diseases drug, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.